Flow cytometry analysis of single-strand DNA damage in neuroblastoma cell lines using the F7-26 monoclonal antibody

Cytometry Part A

Volumn 71, Issue 11, 2007, Pages 951-960

  Grigoryan, Rita S ^a,b,c   Yang, Bo ^a,b   Keshelava, Nino ^a,b,c   Barnhart, Jerry R ^a,b   Reynolds, C Patrick ^a,b,c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Alkylating agents; Apoptosis; Irradiation; Monoclonal antibody; Reactive oxygen species (ROS); Single strand DNA damage

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; FENRETINIDE; HYDROGEN PEROXIDE; MELPHALAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY F7 26; REACTIVE OXYGEN METABOLITE; SINGLE STRANDED DNA; TOPOTECAN; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IRRADIATION; NEUROBLASTOMA CELL; NICK END LABELING; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZYL COMPOUNDS; CELL LINE, TUMOR; CHILD; DNA DAMAGE; DNA, SINGLE-STRANDED; ENZYME INHIBITORS; FENRETINIDE; FLOW CYTOMETRY; GAMMA RAYS; HUMANS; HYDROCARBONS, FLUORINATED; HYDROGEN PEROXIDE; IN SITU NICK-END LABELING; MELPHALAN; NEUROBLASTOMA; OXIDANTS; REACTIVE OXYGEN SPECIES; TOPOTECAN;

EID: 35948938057     PISSN: 15524922     EISSN: 15524930     Source Type: Journal    
DOI: 10.1002/cyto.a.20458     Document Type: Article

References (60)

1. Keshelava N, Zuo JJ, Waidyaratne NS, Triche TJ, Reynolds CP. p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma. Med Pediatr Oncol 2000;35:563-568.
2. Reynolds CP, Seeger RC. Detection of minimal residual disease in bone marrow during or after therapy as a prognostic marker for high-risk neuroblastoma. J Pediatr Hematol Oncol 2001;23:150-152.
3. Reynolds CP, Matthay KK, Villablanca JG, Maurer BJ. Retinoid therapy of high-risk neuroblastoma. Cancer Lett 2003;197:185-192,
4. Anderson CP, Seeger RC, Satake N, Monforte-Munoz HL, Keshelava N, Bailey HH, Reynolds CP. Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line. J Pediatr Hematol Oncol 2001;23:500-505.
5. Anderson CP, Reynolds CP. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy. Bone Marrow Transplant 2002;30:135-140.
6. Keshelava N, Groshen S, Reynolds CP. Cross-resistance of topoisomerase 1 and II inhibitors in neuroblastoma cell lines. Cancer Chemother Pharmacol 2000;45:1-8.
7. Donato ML, Aleman A, Champlin RE, Weber D, Alexanian R, Ippoliti CM, De LM, Anagnostopoulos A, Giralt S. High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: A new regimen for the treatment of multiple myeloma. Leuk Lymphoma 2004;45:755-759.
8. Donfranceseo A, Jenkner A, Castellano A, Ilari I, Milano GM, De SL, Cozza R, Fidani P, Deb G, De Laurent is C. Ifosfamide/earboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age. Acta Paediatr Suppl 2004;93:6-11.
9. Pritchard J, Cotterill SJ, Germond SM, Imeson J, de KJ, Jones DR. High dose melphalan in the treatment of advanced neuroblastoma: Results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group. Pediatr Blood Cancer 2005;44:348-357.
10. Stram DO, Matthay KK, O'Leary M, Reynolds CP, Haase GM, Atkinson JB, Brodeur GM, Seeger RC. Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: A report of two concurrent Children's Cancer Group studies. J Clin Oncol 1996;14:2417-2426.
11. Bignold LP. Alkylating agents and DNA polymerases. Anticancer Res 2006;26:1327-1336.
12. Drablos F, Feyzi E, Aas PA, Vaagbo CB, Kavli B, Bratlie MS, Pena-Diaz J, Otterlei M, Slupphaug G, Krokan HE. Alkylation damage in DNA and RNA - Repair mechanisms and medical significance. DNA Repair (Amst) 2004;3:1389-1407.
13. Ferguson LR, Turner PM, Gourdie TA, Valu KK, Denny WA. 'Petite' mutagenesis and mitotic crossing-over in yeast by DNA-targeted alkylating agents. Mutat Res 1989;215:213-222.
14. Murata M, Suzuki T, Midorikawa K, Oikawa S, Kawanishi S. Oxidative DNA damage induced by a hydroperoxide derivative of cyclophosphamide. Free Radic Biol Med 2004;37:793-802.
15. Povirk LF, Shuker DE. DNA damage and mutagenesis induced by nitrogen mustards. Mutat Res 1994;318:205-226.
16. Sanderson BJ, Shield AJ. Mutagenic damage to mammalian cells by therapeutic alkylating agents. Mutat Res 1996;355:41-57.
17. Shannon AM, Bouchier-Hayes DJ, Condron CM, Toomey D. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev 2003;29:297-307.
18. Caldecott KW. Mammalian DNA single-strand break repair: An X-ra(y)ted affair. Bioessays 2001;23:447-455.
19. Caldecott KW. DNA single-strand breaks and neurodegeneration. DNA Repair (Amst) 2004;3:875-882.
20. Calvet L, Santos A, Valent A, Terrier-Lacombe MJ, Opolon P, Merlin JL, Aubert G, Morizet J, Schellens JH, Benard J. No topoisomerase I alteration in a neuroblastoma model with in vivo acquired resistance to irinotecan. Br J Cancer 2004;91:1205-1212.
21. Chaubey RC, Bhilwade HN, Rajagopalan R, Bannur SV. Gamma ray induced DNA damage in human and mouse leucocytes measured by SCGE-Pro: A software developed for automated image analysis and data processing for Comet assay. Mutat Res 2001;490:187-197.
22. Coleman CN, Cumberlin RL. Translational research in radiation oncology. Int J Radiat Oncol Biol Phys 2001;49:885-890.
23. Cramers P, Atanasova P, Vrolijk H, Darroudi F, van Zeeland AA, Huiskamp R, Mullenders LH, Kleinjans JC. Pre-exposure to low doses: Modulation of X-ray-induced dna damage and repair? Radiat Res 2005;164:383-390.
24. Giagkousiklidis S, Vogler M, Westhoff MA, Kasperczyk H, Debatin KM, Fulda S. Sensitization for gamma-irradiation-induced apoptosis by second mitochondria-derived activator of caspase. Cancer Res 2005;65:10502-10513.
25. O'brien V, Brown R. Signalling cell cycle arrest and cell death through the MMR system. Carcinogenesis 2005;27:682-692.
26. Winters TA, Russell PS, Kohli M, Dar ME, Neumann RD, Jorgensen TJ. Determination of human DNA polymerase utilization for the repair of a model ionizing radiation-induced DNA strand break lesion in a defined vector substrate. Nucleic Acids Res 1999;27:2423-2433.
27. Frankfurt OS. Detection of DNA damage in individual cells by flow cytometric analysis using anti-DNA monoclonal antibody. Exp Cell Res 1987;170:369-380.
28. Frankfurt OS. Decreased stability of DNA in cells treated with alkylating agents. Exp Cell Res 1990;191:181-185.
29. Keshelava N, Seeger RC, Groshen S, Reynolds CP. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res 1998;58:5396-5405.
30. Keshelava N, Zuo JJ, Chen P, Waidyaratne SN, Luna MC, Gomer CJ, Triche TJ, Reynolds CP. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res 2001;61:6185-6193.
31. Maurer BJ, Metelitsa LS, Seeger RC, Cabot MC, Reynolds CP. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines. J Natl Cancer Inst 1999;91:1138-1146.
32. Yang B, Keshelava N, Anderson CP, Reynolds CP. Antagonism of buthionine sulfoximine cytotoxicity for human neuroblastoma cell lines by hypoxia is reversed by the bioreductive agent tirapazamine. Cancer Res 2003;63:1520-1526.
33. Keshelava N, Frgala T, Krejsa J, Kalous O, Reynolds CP. DIMSCAN: A microcomputer fluoroscence-based cytotoxicity assay for preclinical testing of combination chemotherapy. Methods Mol Med 2005;110:139-153.
34. Proffitt RT, Tran JV, Reynolds CP. A fluorescence digital image microscopy system for quantifying relative cell numbers in tissue culture plates. Cytometry 1996;24:204-213.
35. Baldetorp B, Stal O, Ahrens O, Cornelisse C, Corver W, Falkmer U, Ferno M. Different calculation methods for flow cytometric S-phase fraction: Prognostic implications in breast cancer? Cytometry 1998;33:385-393.
36. Jourdan ML, Ferrero-Pous M, Spyratos F, Romain S, Martin PM, Chassevent A. Flow cytometric S-phase fraction measurement in breast carcinoma: Influence of software and histogram resolution. Cytometry 2002;48:66-70.
37. Sakahira H, Enari M, Nagata S. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature 1998;391:96-99.
38. Higuchi Y. Chromosomal DNA fragmentation in apoptosis and necrosis induced by oxidative stress. Biochem Pharmacol 2003;66:1527-1535.
39. Izumi T, Hazra TK, Boldogh I, Tomkinson AE, Park MS, Ikeda S, Mitra S. Requirement for human AP endonuclease 1 for repair of 3′-blocking damage at DNA single-strand breaks induced by reactive oxygen species. Carcinogenesis 2000;21:1329-1334.
40. Delia D, Aiello A, Formelli F, Fontanella E, Costa A, Miyashita T, Reed JC, Pierotti MA. Regulation of apoptosis induced by the retinoid N-(4-hydroxyphenyl) retinamide and effect of deregulated bcl-2. Blood 1995;85:359-367.
41. Shen JC, Wang TT, Chang S, Hursting SD. Mechanistic studies of the effects of the retinoid N-(4-hydroxyphenyl)retinamide on prostate cancer cell growth and apoptosis. Mol Carcinog 1999;24:160-168.
42. Foray N, Charvet AM, Duchemin D, Favaudon V, Lavalette D. The repair rate of radiation-induced DNA damage: A stochastic interpretation based on the gamma function. J Theor Biol 2005;236:448-458.
43. Short SC, Bourne S, Martindale C, Woodcock M, Jackson SP. DNA damage responses at low radiation doses. Radiat Res 2005;164:292-302.
44. Zhang K, Taylor JS. Phototriggered formation and repair of DNA containing a site-specific single strand break of the type produced by ionizing radiation or AP lyase activity. Biochemistry 2001;40:153-159.
45. Davoli MA, Ren Y, Zhu Y, Fourtounis J, Jones C, Robertson GS, Ng GY, Xu D. Automated analysis of global ischemia-induced CA1 neuronal death using terminal UTP nick end labeling (TUNEL). J Neurosci Methods 2002;115:55-61.
46. Hara A, Niwa M, Iwai T, Nakashima M, Bunai Y, Uematsu T, Yoshimi N, Mori H. Neuronal apoptosis studied by a sequential TUNEL technique: A method for tract-tracing. Brain Res Brain Res Protoc 1999;4:140-146.
47. Loo DT. TUNEL assay. An overview of techniques. Methods Mol Biol 2002;203:21-30.
48. Stecco C, Porzionato A, Macchi V, Sarasin G, Calcagno A, Parenti A, De CR. Detection of apoptosis in human brainstem by TUNEL assay. Ital J Anat Embryol 2005;110:255-260.
49. Tice RR, Agurell E, Anderson D, Burlinson B, Hartmann A, Kobayashi H, Miyamae Y, Rojas E, Ryu JC, Sasaki YF. Single cell gel/comet assay: Guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 2000;35:206-221.
50. Wojewodzka M, Buraczewska I, Kruszewski M. A modified neutral comet assay: Elimination of lysis at high temperature and validation of the assay with anti-single-stranded DNA antibody. Mutat Res 2002;518:9-20.
51. Yasuhara S, Perez ME, Kanakubo E, Yasuhara Y, Shin YS, Kaneki M, Fujita T, Martyn JA. Skeletal muscle apoptosis after burns is associated with activation of proapoptotic signals. Am J Physiol Endocrinol Metab 2000;279:E1114-E1121.
52. Yasuhara S, Zhu Y, Matsui T, Tipirneni N, Yasuhara Y, Kaneki M, Rosenzweig A, Martyn JA. Comparison of comet assay, electron microscopy, and flow cytometry for detection of apoptosis. J Histochem Cytochem 2003;51:873-885.
53. Saraste A. Morphologic criteria and detection of apoptosis. Herz 1999;24:189-195.
54. Bihari N, Batel R, Jorsic Z, Muller WE, Waldmann P, Zahn RK. Comparison between the comet assay and fast micromethod for measuring DNA damage in HeLA cells. Croat Chem Acta 2002;75:793-804.
55. Henderson L, Wolfreys A, Fedyk J, Bourner C, Windebank S. The ability of the Comet assay to discriminate between genotoxins and cytotoxins. Mutagenesis 1998;13:89-94.
56. Ward JF. Radiation mutagenesis: The initial DNA lesions responsible. Radiat Res 1995;142:362-368.
57. Friedberg EC. Suffering in silence: The tolerance of DNA damage. Nat Rev Mol Cell Biol 2005;6:943-953.
58. Rodemann HP, Baumann M, Bodis S, Dikomey E. Molecular radiation biology/oncology. Radiother Oncol 2004;72:247-249.
59. Yanagihara K, Nii M, Numoto M, Kamiya K, Tauchi H, Sawada S, Seito T. Radiation-induced apoptotic cell death in human gastric epithelial tumour cells; correlation between mitotic death and apoptosis. Int J Radiat Biol 1995;67:677-685.
60. Yanagihara K. [Radiation induced apoptosis in cultured human epithelial tumor cells]. Nippon Rinsho 1996;54:1943-1948.